Oncothyreon Inc (ONTY) 1.57 $ONTY
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 8:12AM CST
HRS: 77.73 (+0.42), GPRO: 45.27 (-0.02), NLST: 1.86 (unch), TROV: 4.99 (-0.17), AU: 12.33 (+0.36), NMM: 12.37 (+0.24), EOX: 1.15 (unch), NBG: 1.61 (+0.18), ONTY: 1.57 (unch), ATVI: 23.11 (+0.17), PBR: 6.98 (+0.44), XLS: 24.15 (+0.04), MHR: 2.62 (+0.11), CIG: 4.29 (+0.10), PWE: 2.45 (+0.02), LNKD: 269.00 (+1.83), GDP: 3.58 (+0.29), SFY: 2.91 (+0.26), P: 15.44 (+0.45), TPX: 55.62 (+1.71), EXPE: 89.49 (-0.08), OHRP: 7.38 (-0.30), TWTR: 48.50 (+0.55), YELP: 47.53 (-0.10)
Oncothyreon prices offerings
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 8:02AM CST
ONTY: 1.57 (unch)
Oncothyreon Prices $22 Million Concurrent Public Offerings of Common Stock and Preferred Stock
GlobeNewswire - Fri Feb 06, 7:49AM CST
Oncothyreon Inc. (Nasdaq:ONTY) today announced the pricing of previously announced concurrent but separate underwritten offerings of 13,500,000 shares of its Common Stock at a price to the public of $1.50 per share, for expected gross proceeds of approximately $20 million and 1,333 shares of its Series B Convertible Preferred Stock at a price to the public of $1,500 per share, for expected gross proceeds of approximately $2 million. Each share of Series B Convertible Preferred Stock is non-voting and convertible into 1,000 shares of Oncothyreon Common Stock, provided that conversion will be prohibited if, as a result, the holder and its affiliates would beneficially own more than 4.99% of the Common Stock then outstanding. As part of the Common Stock offering, Oncothyreon also granted the underwriters a 30-day option to purchase 2,025,000 additional shares of Oncothyreon Common Stock. The offerings are being conducted as separate public offerings by means of separate prospectus supplements, and neither offering is contingent upon the consummation of the other.
ONTY: 1.57 (unch)
Oncothyreon prepares for equity offering
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 3:16PM CST
ONTY: 1.57 (unch)
Oncothyreon Announces Proposed Public Offerings
GlobeNewswire - Thu Feb 05, 3:09PM CST
Oncothyreon Inc. (Nasdaq:ONTY) today announced that it intends to offer and sell shares of its Common Stock and Series B Convertible Preferred Stock in separate but concurrent underwritten public offerings. The Series B Convertible Preferred Stock is non-voting and convertible into shares of Oncothyreon Common Stock, provided that conversion will be prohibited if, as a result, the holder and its affiliates would beneficially own more than 4.99% of the Common Stock then outstanding. As part of the Common Stock offering, Oncothyreon also expects to grant the underwriters a 30-day option to purchase additional shares of its Common Stock. The offerings are being conducted as separate public offerings by means of separate prospectus supplements, and neither offering is contingent upon the consummation of the other. The offerings are subject to market conditions and there can be no assurance as to whether or when the offerings may be completed, or as to the actual size or terms of the offerings.
ONTY: 1.57 (unch)
Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75+ Companies Operating in this Market
M2 - Mon Feb 02, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/jkszvl/biomarker) has announced the addition of the "Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75 Companies Operating in this Market" report to their offering. Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor's offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer. The purpose of this publications report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Market Analysis of the Cancer Biomarkers Space 4. Major Clinical Applications of Cancer Biomarkers 5. Breast Cancer 6. Ovarian Cancer 7. Prostate Cancer 8. Bladder Cancer 9. Colorectal Cancer 10. Genetic Diagnostics Set to Revolutionize Cancer Diagnostic Testing 11. Leukemia Biomarkers 12. Lung Cancer 13. Enabling Technologies for Oncology Biomarker Discovery 14. Biomarker Tests Co-Developed with Cancer Therapeutics as Companion Diagnostics 15. Companion Diagnostics and Personalized Medicine: Biology, Approaches, Pipeline and Regulatory Trends 16. Business Trends in the Industry 17. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms Companies Mentioned: Click below to view full list of companies - Abbott Diagnostics - Affymetrix, Inc. - Agendia BV - Agensys, Inc. (Astellas Pharma US) - Agilent Technologies - Beckman Coulter, Inc. - Biocode Hycel S.A. - BioCurex, Inc. - Biomarker Technologies, LLC - Biomedical Diagnostics, LLC - Biomerica, Inc. - bioM?rieux - Cangen Biotechnologies, Inc. - DRG International, Inc. - EDP Biotech Corporation - Eisai Co., Ltd. - Eli Lilly & Co. - Immunomedics, Inc. - Incyte Pharmaceuticals, Inc. - InterGenetics, Inc. - Ipsogen (Qiagen Marseille) - Mitsubishi Kagaku Medical - MolecularMD - Myriad Genetics, Inc. - Oncothyreon, Inc. (Formerly known as Biomira) - OPKO Health, Inc. - Roche Molecular Diagnostics - SensiGen, LLC (Sequenom Center for Molecular Medicine) - Siemens Healthcare Diagnostics, Inc. - Vermillion, Inc. (Formerly Ciphergen) For more information visit http://www.researchandmarkets.com/research/jkszvl/biomarker
MYGN: 34.03 (+0.40), IMMU: 3.84 (unch), A: 40.15 (+0.13), INCY: 75.94 (+0.28), LLY: 70.56 (+0.03), ONTY: 1.57 (unch), VRML: 2.08 (+0.12), AFFX: 11.45 (+0.02), SQNM: 3.62 (unch), OPK: 13.80 (-0.28)
Adimab Announces New Partnerships with Acceleron, Oncothyreon, Surface Oncology and Potenza
Business Wire - Fri Jan 09, 8:45AM CST
Adimab, LLC, the technology leader in the discovery of monoclonal and bispecific antibodies, today announced independent discovery collaborations with Acceleron Pharma, Inc., Oncothyreon, Inc., Surface Oncology and Potenza Therapeutics, Inc. All four collaborations are structured as funded discovery programs in which Adimab will discover and optimize therapeutic monoclonal or bispecific antibodies against multiple targets for each partner.
MRK: 58.81 (-0.07), ONTY: 1.57 (unch), XLRN: 38.02 (+0.07)
Oncothyreon (ONTY) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 7:42AM CST
Oncothyreon is one stock that might be an intriguing choice for investors as it is seeing solid earnings estimate revision and has a Zacks Industry Rank of 58
ONTY: 1.57 (unch)
Biotech Weekly: Top Ideas From The San Antonio Breast Cancer Symposium
Daniel Ward - Seeking Alpha - Tue Dec 16, 10:00AM CST
Approaching 7,500 scientists, advocates, professors, and healthcare professional descended upon the San Antonio Riverwalk to present and discuss groundbreaking research in the field of breast cancer at the San Antonio Breast Cancer Symposium (SABCS)...
ONTY: 1.57 (unch), CELGZ: 3.17 (-0.04), CELG: 115.88 (+0.16)
Oncothyreon Up on Gaining License to Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 5:05PM CST
Shares of Oncothyreon Inc. (ONTY) soared 18.1% after it announced an exclusive license agreement with Array.
ONTY: 1.57 (unch)
Hot Stock: Oncothyreon, Shares Drop 8.8% (ONTY)
Comtex SmarTrend(R) - Mon Dec 15, 10:36AM CST
Oncothyreon (NASDAQ:ONTY) is one of today's worst performing low-priced stocks, down 8.8% to $1.86 on 2.4x average daily volume. Oncothyreon has traded 1.2 million shares thus far today, vs. average volume of 511,000 shares per day. The stock has underperformed the Dow (-8.8% to the Dow's -0.7%) and underperformed the S&P 500 (-8.8% to the S&P's -0.6%) during today's trading.
ONTY: 1.57 (unch)
Hot Stock: Oncothyreon, Shares Gain 5.3% (ONTY)
Comtex SmarTrend(R) - Fri Dec 12, 10:06AM CST
Oncothyreon (NASDAQ:ONTY) is one of today's best performing low-priced stocks, up 5.3% to $1.80 on 2.8x average daily volume. Oncothyreon has traded 1.4 million shares thus far today, vs. average volume of 508,000 shares per day. The stock has outperformed the Dow (5.3% to the Dow's -1.0%) and outperformed the S&P 500 (5.3% to the S&P's -0.9%) during today's trading.
ONTY: 1.57 (unch)
Oncothyreon secures exclusive license to HER2 inhibitor
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 9:50AM CST
ONTY: 1.57 (unch), ARRY: 8.05 (+0.08)
Oncothyreon Announces Presentation of Positive ONT-380 Data at San Antonio Breast Cancer Symposium
GlobeNewswire - Fri Dec 12, 6:11AM CST
Oncothyreon Inc. (Nasdaq:ONTY) today announced that positive preliminary data from two ongoing Phase 1b trials of ONT-380 (ARRY-380), an orally active, reversible and selective small molecule HER2 inhibitor, will be presented at the San Antonio Breast Cancer Symposium.
ONTY: 1.57 (unch)
Oncothyreon Announces Exclusive License Agreement With Array BioPharma for ONT-380
GlobeNewswire - Fri Dec 12, 6:00AM CST
Oncothyreon Inc. (Nasdaq:ONTY) today announced that Array BioPharma Inc. (Nasdaq:ARRY) has granted Oncothyreon an exclusive license to develop, manufacture and commercialize ONT-380 (ARRY-380), an orally active, reversible and selective small molecule HER2 inhibitor. The license agreement replaces the prior Development and Collaboration Agreement under which Oncothyreon and Array were jointly developing ONT-380.
ONTY: 1.57 (unch), ARRY: 8.05 (+0.08)
Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST
HTBX: 5.83 (+0.22), BIB: 141.30 (+2.39), INCY: 75.94 (+0.28), PFE: 34.64 (-0.23), IBB: 323.46 (+3.04), DRGS: 56.69 (unch), BIND: 6.06 (+0.21), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), ONTY: 1.57 (unch), ECYT: 5.26 (-0.02), BIS: 39.67 (-0.75), CLVS: 68.79 (+0.71), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), ARIA: 7.35 (+0.45), IRY: 49.63 (+0.34), IXJ: 104.21 (+0.61), FPRX: 24.63 (+0.63)
Oncothyreon Inc. (ONTY) in Focus: Stock Surges 10.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 7:44AM CST
Oncothyreon Inc. (ONTY) was a big mover last session, as the company saw its shares rise slightly over 10% on the day
BIIB: 391.66 (-0.45), ILMN: 198.54 (+1.81), AMAG: 41.49 (+0.23), ONTY: 1.57 (unch)
Oncothyreon Up 8.9%, Shares Break Through Resistance (ONTY)
Comtex SmarTrend(R) - Wed Nov 26, 11:35AM CST
Oncothyreon (NASDAQ:ONTY) is one of today's best performing low-priced stocks, up 8.9% to $1.84 on 1.8x average daily volume. Thus far today, Oncothyreon has traded 817,000 shares, vs. average volume of 460,000 shares per day. The stock has outperformed the Dow (8.9% to the Dow's -0.1%) and outperformed the S&P 500 (8.9% to the S&P's 0.1%) during today's trading.
ONTY: 1.57 (unch)
Oncothyreon to Present at Stifel 2014 Healthcare Conference
GlobeNewswire - Wed Nov 12, 7:01AM CST
Oncothyreon Inc. (Nasdaq:ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Stifel 2014 Healthcare Conference in New York on Wednesday, Nov. 19, 2014 at 3:00 p.m. Eastern.
ONTY: 1.57 (unch)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 8:12AM CST
HRS: 77.73 (+0.42), GPRO: 45.27 (-0.02), NLST: 1.86 (unch), TROV: 4.99 (-0.17), AU: 12.33 (+0.36), NMM: 12.37 (+0.24), EOX: 1.15 (unch), NBG: 1.61 (+0.18), ONTY: 1.57 (unch), ATVI: 23.11 (+0.17), PBR: 6.98 (+0.44), XLS: 24.15 (+0.04), MHR: 2.62 (+0.11), CIG: 4.29 (+0.10), PWE: 2.45 (+0.02), LNKD: 269.00 (+1.83), GDP: 3.58 (+0.29), SFY: 2.91 (+0.26), P: 15.44 (+0.45), TPX: 55.62 (+1.71), EXPE: 89.49 (-0.08), OHRP: 7.38 (-0.30), TWTR: 48.50 (+0.55), YELP: 47.53 (-0.10)
Oncothyreon prices offerings
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 8:02AM CST
ONTY: 1.57 (unch)
Oncothyreon Prices $22 Million Concurrent Public Offerings of Common Stock and Preferred Stock
GlobeNewswire - Fri Feb 06, 7:49AM CST
Oncothyreon Inc. (Nasdaq:ONTY) today announced the pricing of previously announced concurrent but separate underwritten offerings of 13,500,000 shares of its Common Stock at a price to the public of $1.50 per share, for expected gross proceeds of approximately $20 million and 1,333 shares of its Series B Convertible Preferred Stock at a price to the public of $1,500 per share, for expected gross proceeds of approximately $2 million. Each share of Series B Convertible Preferred Stock is non-voting and convertible into 1,000 shares of Oncothyreon Common Stock, provided that conversion will be prohibited if, as a result, the holder and its affiliates would beneficially own more than 4.99% of the Common Stock then outstanding. As part of the Common Stock offering, Oncothyreon also granted the underwriters a 30-day option to purchase 2,025,000 additional shares of Oncothyreon Common Stock. The offerings are being conducted as separate public offerings by means of separate prospectus supplements, and neither offering is contingent upon the consummation of the other.
ONTY: 1.57 (unch)
Oncothyreon prepares for equity offering
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 3:16PM CST
ONTY: 1.57 (unch)
Oncothyreon Announces Proposed Public Offerings
GlobeNewswire - Thu Feb 05, 3:09PM CST
Oncothyreon Inc. (Nasdaq:ONTY) today announced that it intends to offer and sell shares of its Common Stock and Series B Convertible Preferred Stock in separate but concurrent underwritten public offerings. The Series B Convertible Preferred Stock is non-voting and convertible into shares of Oncothyreon Common Stock, provided that conversion will be prohibited if, as a result, the holder and its affiliates would beneficially own more than 4.99% of the Common Stock then outstanding. As part of the Common Stock offering, Oncothyreon also expects to grant the underwriters a 30-day option to purchase additional shares of its Common Stock. The offerings are being conducted as separate public offerings by means of separate prospectus supplements, and neither offering is contingent upon the consummation of the other. The offerings are subject to market conditions and there can be no assurance as to whether or when the offerings may be completed, or as to the actual size or terms of the offerings.
ONTY: 1.57 (unch)
Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75+ Companies Operating in this Market
M2 - Mon Feb 02, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/jkszvl/biomarker) has announced the addition of the "Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75 Companies Operating in this Market" report to their offering. Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor's offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer. The purpose of this publications report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Market Analysis of the Cancer Biomarkers Space 4. Major Clinical Applications of Cancer Biomarkers 5. Breast Cancer 6. Ovarian Cancer 7. Prostate Cancer 8. Bladder Cancer 9. Colorectal Cancer 10. Genetic Diagnostics Set to Revolutionize Cancer Diagnostic Testing 11. Leukemia Biomarkers 12. Lung Cancer 13. Enabling Technologies for Oncology Biomarker Discovery 14. Biomarker Tests Co-Developed with Cancer Therapeutics as Companion Diagnostics 15. Companion Diagnostics and Personalized Medicine: Biology, Approaches, Pipeline and Regulatory Trends 16. Business Trends in the Industry 17. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms Companies Mentioned: Click below to view full list of companies - Abbott Diagnostics - Affymetrix, Inc. - Agendia BV - Agensys, Inc. (Astellas Pharma US) - Agilent Technologies - Beckman Coulter, Inc. - Biocode Hycel S.A. - BioCurex, Inc. - Biomarker Technologies, LLC - Biomedical Diagnostics, LLC - Biomerica, Inc. - bioM?rieux - Cangen Biotechnologies, Inc. - DRG International, Inc. - EDP Biotech Corporation - Eisai Co., Ltd. - Eli Lilly & Co. - Immunomedics, Inc. - Incyte Pharmaceuticals, Inc. - InterGenetics, Inc. - Ipsogen (Qiagen Marseille) - Mitsubishi Kagaku Medical - MolecularMD - Myriad Genetics, Inc. - Oncothyreon, Inc. (Formerly known as Biomira) - OPKO Health, Inc. - Roche Molecular Diagnostics - SensiGen, LLC (Sequenom Center for Molecular Medicine) - Siemens Healthcare Diagnostics, Inc. - Vermillion, Inc. (Formerly Ciphergen) For more information visit http://www.researchandmarkets.com/research/jkszvl/biomarker
MYGN: 34.03 (+0.40), IMMU: 3.84 (unch), A: 40.15 (+0.13), INCY: 75.94 (+0.28), LLY: 70.56 (+0.03), ONTY: 1.57 (unch), VRML: 2.08 (+0.12), AFFX: 11.45 (+0.02), SQNM: 3.62 (unch), OPK: 13.80 (-0.28)
Adimab Announces New Partnerships with Acceleron, Oncothyreon, Surface Oncology and Potenza
Business Wire - Fri Jan 09, 8:45AM CST
Adimab, LLC, the technology leader in the discovery of monoclonal and bispecific antibodies, today announced independent discovery collaborations with Acceleron Pharma, Inc., Oncothyreon, Inc., Surface Oncology and Potenza Therapeutics, Inc. All four collaborations are structured as funded discovery programs in which Adimab will discover and optimize therapeutic monoclonal or bispecific antibodies against multiple targets for each partner.
MRK: 58.81 (-0.07), ONTY: 1.57 (unch), XLRN: 38.02 (+0.07)
Oncothyreon (ONTY) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 7:42AM CST
Oncothyreon is one stock that might be an intriguing choice for investors as it is seeing solid earnings estimate revision and has a Zacks Industry Rank of 58
ONTY: 1.57 (unch)
Biotech Weekly: Top Ideas From The San Antonio Breast Cancer Symposium
Daniel Ward - Seeking Alpha - Tue Dec 16, 10:00AM CST
Approaching 7,500 scientists, advocates, professors, and healthcare professional descended upon the San Antonio Riverwalk to present and discuss groundbreaking research in the field of breast cancer at the San Antonio Breast Cancer Symposium (SABCS)...
ONTY: 1.57 (unch), CELGZ: 3.17 (-0.04), CELG: 115.88 (+0.16)
Oncothyreon Up on Gaining License to Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 5:05PM CST
Shares of Oncothyreon Inc. (ONTY) soared 18.1% after it announced an exclusive license agreement with Array.
ONTY: 1.57 (unch)
Hot Stock: Oncothyreon, Shares Drop 8.8% (ONTY)
Comtex SmarTrend(R) - Mon Dec 15, 10:36AM CST
Oncothyreon (NASDAQ:ONTY) is one of today's worst performing low-priced stocks, down 8.8% to $1.86 on 2.4x average daily volume. Oncothyreon has traded 1.2 million shares thus far today, vs. average volume of 511,000 shares per day. The stock has underperformed the Dow (-8.8% to the Dow's -0.7%) and underperformed the S&P 500 (-8.8% to the S&P's -0.6%) during today's trading.
ONTY: 1.57 (unch)
Hot Stock: Oncothyreon, Shares Gain 5.3% (ONTY)
Comtex SmarTrend(R) - Fri Dec 12, 10:06AM CST
Oncothyreon (NASDAQ:ONTY) is one of today's best performing low-priced stocks, up 5.3% to $1.80 on 2.8x average daily volume. Oncothyreon has traded 1.4 million shares thus far today, vs. average volume of 508,000 shares per day. The stock has outperformed the Dow (5.3% to the Dow's -1.0%) and outperformed the S&P 500 (5.3% to the S&P's -0.9%) during today's trading.
ONTY: 1.57 (unch)
Oncothyreon secures exclusive license to HER2 inhibitor
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 9:50AM CST
ONTY: 1.57 (unch), ARRY: 8.05 (+0.08)
Oncothyreon Announces Presentation of Positive ONT-380 Data at San Antonio Breast Cancer Symposium
GlobeNewswire - Fri Dec 12, 6:11AM CST
Oncothyreon Inc. (Nasdaq:ONTY) today announced that positive preliminary data from two ongoing Phase 1b trials of ONT-380 (ARRY-380), an orally active, reversible and selective small molecule HER2 inhibitor, will be presented at the San Antonio Breast Cancer Symposium.
ONTY: 1.57 (unch)
Oncothyreon Announces Exclusive License Agreement With Array BioPharma for ONT-380
GlobeNewswire - Fri Dec 12, 6:00AM CST
Oncothyreon Inc. (Nasdaq:ONTY) today announced that Array BioPharma Inc. (Nasdaq:ARRY) has granted Oncothyreon an exclusive license to develop, manufacture and commercialize ONT-380 (ARRY-380), an orally active, reversible and selective small molecule HER2 inhibitor. The license agreement replaces the prior Development and Collaboration Agreement under which Oncothyreon and Array were jointly developing ONT-380.
ONTY: 1.57 (unch), ARRY: 8.05 (+0.08)
Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST
HTBX: 5.83 (+0.22), BIB: 141.30 (+2.39), INCY: 75.94 (+0.28), PFE: 34.64 (-0.23), IBB: 323.46 (+3.04), DRGS: 56.69 (unch), BIND: 6.06 (+0.21), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), ONTY: 1.57 (unch), ECYT: 5.26 (-0.02), BIS: 39.67 (-0.75), CLVS: 68.79 (+0.71), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), ARIA: 7.35 (+0.45), IRY: 49.63 (+0.34), IXJ: 104.21 (+0.61), FPRX: 24.63 (+0.63)
Oncothyreon Inc. (ONTY) in Focus: Stock Surges 10.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 7:44AM CST
Oncothyreon Inc. (ONTY) was a big mover last session, as the company saw its shares rise slightly over 10% on the day
BIIB: 391.66 (-0.45), ILMN: 198.54 (+1.81), AMAG: 41.49 (+0.23), ONTY: 1.57 (unch)
Oncothyreon Up 8.9%, Shares Break Through Resistance (ONTY)
Comtex SmarTrend(R) - Wed Nov 26, 11:35AM CST
Oncothyreon (NASDAQ:ONTY) is one of today's best performing low-priced stocks, up 8.9% to $1.84 on 1.8x average daily volume. Thus far today, Oncothyreon has traded 817,000 shares, vs. average volume of 460,000 shares per day. The stock has outperformed the Dow (8.9% to the Dow's -0.1%) and outperformed the S&P 500 (8.9% to the S&P's 0.1%) during today's trading.
ONTY: 1.57 (unch)
Oncothyreon to Present at Stifel 2014 Healthcare Conference
GlobeNewswire - Wed Nov 12, 7:01AM CST
Oncothyreon Inc. (Nasdaq:ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Stifel 2014 Healthcare Conference in New York on Wednesday, Nov. 19, 2014 at 3:00 p.m. Eastern.
ONTY: 1.57 (unch)
